Chugai Pharmaceutical Co (TSE:4519) Stock Based Compensation : 円0 Mil (TTM As of Mar. 2025)

View and export this data going back to 1956. Start your Free Trial

What is Chugai Pharmaceutical Co Stock Based Compensation?

Chugai Pharmaceutical Co's Stock Based Compensation for the three months ended in Mar. 2025 was 円0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was 円0 Mil.

Chugai Pharmaceutical Co Stock Based Compensation Historical Data

The historical data trend for Chugai Pharmaceutical Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Stock Based Compensation Chart

Chugai Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Stock Based Compensation

Get a 7-Day Free Trial

Chugai Pharmaceutical Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Stock Based Compensation	Get a 7-Day Free Trial															-	-	-	-	-

Chugai Pharmaceutical Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

Chugai Pharmaceutical Co Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (TSE:4519) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

CHGCY:USA CHGCF:USA 4519N:Mexico CUP:Germany

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and Actemra for treating rheumatoid arthritis and covid patients.

Chugai Pharmaceutical Co Headlines

No Headlines